TIDMEVG

RNS Number : 7659C

Evgen Pharma PLC

19 June 2019

 
 For immediate release   19 June 2019

Evgen Pharma plc

("Evgen" or "the Company")

Posting of Annual Report and AGM Notice

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that its Annual Report and Accounts for the year ending 31 March 2019 together with the notice of Annual General Meeting ("AGM") have today been posted to shareholders.

The documents are being made available at the investor relations section of the Company's website, www.evgen.com.

The Company's AGM will be held at 2.00pm at the offices of RSM UK Audit LLP, 3 Hardman Street, Manchester M3 7HF on Thursday 18 July 2019.

Enquiries:

 
 Evgen Pharma plc                                c/o +44 (0) 20 7466 5000 
  Dr Stephen Franklin, CEO 
  Richard Moulson, CFO 
  www.evgen.com 
 finnCap 
  Geoff Nash, Teddy Whiley (Corporate 
  Finance) 
  Alice Lane, Manasa Patil (ECM) 
  www.finncap.com                                    +44 (0) 20 7220 0500 
 WG Partners LLP 
  Nigel Barnes, Claes Spång                     +44 (0) 20 3705 9330 
 Buchanan 
  Mark Court, Sophie Wills, Tilly 
  Abraham 
  evgen@buchanan.uk.com                              +44 (0) 20 7466 5000

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOAGCGDLLXBBGCC

(END) Dow Jones Newswires

June 19, 2019 05:39 ET (09:39 GMT)

Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Evgen Pharma Charts.
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Evgen Pharma Charts.